ProCE Banner Activity

Immune Checkpoint Inhibitor Therapy for HER2-Negative Early-Stage Breast Cancer

Slideset

Expert slides from Tanya Gupta, MD, on key data supporting immune checkpoint inhibitor–based therapy for treatment of early-stage triple-negative breast cancer.

Released: May 16, 2024

Expiration: May 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Breastcancer.org

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme, LLC, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner